Biochemical consequences of bariatric surgery for extreme clinical obesity

Annals of Clinical Biochemistry

Volumn 53, Issue 1, 2016, Pages 21-31

  Sarker, Anita ^a   Meek, Claire L ^a,b   Park, Adrian ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

clinical studies; Nutrition

Indexed keywords

CALCIUM; CALCIUM CARBONATE; CHOLECYSTOKININ; CITRATE CALCIUM; COPPER; CYANOCOBALAMIN; FOLIC ACID; GHRELIN; GLUCAGON LIKE PEPTIDE 1; IRON; PEPTIDE YY; PROBIOTIC AGENT; RETINOL; THIAMINE; VITAMIN D; VITAMIN K GROUP;

BACTERIAL OVERGROWTH; BARIATRIC SURGERY; BILIOPANCREATIC BYPASS; BIOCHEMICAL ANALYSIS; BODY MASS; CALCIUM DEFICIENCY; CLINICAL LABORATORY; COPPER DEFICIENCY; CYANOCOBALAMIN DEFICIENCY; DUMPING SYNDROME; FOLIC ACID DEFICIENCY; GALLSTONE; GASTRIC BANDING; GASTROINTESTINAL TRACT FUNCTION; GOUT; HUMAN; HYPEROXALURIA; HYPOGLYCEMIA; IRON ABSORPTION; IRON DEFICIENCY; LAPAROSCOPIC SURGERY; MACRONUTRIENT; MALABSORPTION; MALNUTRITION; MINERAL SUPPLEMENTATION; MORBID OBESITY; NEPHROLITHIASIS; NUTRITIONAL ASSESSMENT; NUTRITIONAL DEFICIENCY; NUTRITIONAL SUPPORT; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RETINOL DEFICIENCY; REVIEW; ROUX Y ANASTOMOSIS; SLEEVE GASTRECTOMY; SMALL INTESTINE ABSORPTION; STOMACH BYPASS; THIAMINE DEFICIENCY; VITAMIN D DEFICIENCY; VITAMIN K DEFICIENCY; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION; ZINC DEFICIENCY; ADVERSE EFFECTS; COMPLICATION; METABOLISM; OBESITY, MORBID; PROCEDURES; TREATMENT OUTCOME;

BARIATRIC SURGERY; HUMANS; NUTRITION ASSESSMENT; OBESITY, MORBID; TREATMENT OUTCOME;

EID: 84950308196     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1177/0004563215588116     Document Type: Review

References (59)

1. World Health Organization. Ten facts on obesity 2013, http://www.who.int/features/factfiles/obesity/en/index.html (accessed 5 September 2013)
2. Statistics on obesity, physical activity and diet: England, 2010. The NHS Information Centre for health and social care, Lifestyles Statistics, 2010
3. B.J.S.ButlandP.Kopelman. Tackling obesities: future choices – project report, 2nd ed. London: Foresight Programme of the Government Office for Science, 2007.
4. J.L.ColquittJ.PicotE.Loveman. Surgery for obesity. Cochrane Database Syst Rev2009; 15: CD003641–CD003641.
5. C.L.KeatingJ.B.DixonM.L.Moodie. Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis. Diabetes Care2009; 32: 567–574.
6. Obesity: identification, assessment and management of overweight and obesity in children, young people and adults. National Institute for Clinical Excellence, clinical guideline 189, 2014
7. R.V.CohenJ.C.PinheiroC.A.Schiavon. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care2012; 35: 1420–1428.
8. M.FriedV.YumukJ.M.Oppert. Interdisciplinary European Guidelines on metabolic and bariatric surgery. Obes Facts2013; 6: 449–468.
9. L.Sjöström. Review of the key results from the Swedish Obese Subjects (SOS) trial – a prospective controlled intervention study of bariatric surgery. J Intern Med2013; 273: 219–234.
10. L.SjöströmK.NarbroC.D.Sjöström. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med2007; 357: 741–752.
11. L.M.CarlssonM.PeltonenS.Ahlin. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med2012; 367: 695–704.
12. L.SjöströmA.GummessonC.D.Sjöström. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol2009; 10: 653–662.
13. Noel Wathion EMA. Public Statement on Acomplia (rimonabant). Withdrawal of the Marketing Authorisation in the European Union 2009
14. Administration USFaD. Meridia (sibutramine): Market Withdrawal Due to Risk of Serious Cardiovascular Events, 2010
15. L.SjöströmA.RissanenT.Andersen. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet1998; 352: 167–172.
16. Bariatric surgery for obesity. NHS National Obesity Observatory (NOO), 2010
17. E.V.KotidisG.G.KoliakosV.G.Baltzopoulos. Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment—a prospective study. Obes Surg2006; 16: 1425–1432.
18. P.E.O’Brien. Bariatric surgery: mechanisms, indications and outcomes. J Gastroenterol Hepatol2010; 25: 1358–1365.
19. J.P.SczepaniakM.L.OwensH.Shukla. Comparability of weight loss reporting after gastric bypass and sleeve gastrectomy using BOLD data 2008–2011. Obes Surg2015; 25(5): 788–795.
20. S.PanunziA.De GaetanoA.Carnicelli. Predictors of remission of diabetes mellitus in severely obese individuals undergoing bariatric surgery: do BMI or procedure choice matter? A meta-analysis. Ann Surg2015; 261(3): 459–467.
21. J.J.Holst. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Curr Opin Pharmacol2013; 13: 983–988.
22. J.J.Holst. The physiology of glucagon-like peptide 1. Physiol Rev2007; 87: 1409–1439.
23. R.PeterliR.E.SteinertB.Woelnerhanssen. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. Obes Surg2012; 22: 740–748.
24. P.W.van RutteM.D.LuyerI.H.de Hingh. To sleeve or NOT to sleeve in bariatric surgery?ISRN Surg2012; 2012: 674042–674042.
25. B.ErnstM.ThurnheerS.M.Schmid. Evidence for the necessity to systematically assess micronutrient status prior to bariatric surgery. Obes Surg2009; 19: 66–73.
26. S.Vanlint. Vitamin D and obesity. Nutrients2013; 5: 949–956.
27. O.ZieglerM.A.SirveauxL.Brunaud. Medical follow up after bariatric surgery: nutritional and drug issues. General recommendations for the prevention and treatment of nutritional deficiencies. Diabetes Metab2009; 35: 544–557.
28. J.I.MechanickA.YoudimD.B.Jones. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient—2013 update: cosponsored by American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery. Endocr Pract2013; 19: 337–372.
29. C.W.le RouxS.J.AylwinR.L.Batterham. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg2006; 243: 108–114.
30. M.BoseJ.TeixeiraB.Olivan. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery. J Diabetes2010; 2: 47–55.
31. R.Taylor. Banting Memorial lecture 2012: reversing the twin cycles of type 2 diabetes. Diabet Med2013; 30: 267–275.
32. B.Laferrère. Diabetes remission after bariatric surgery: is it just the incretins?Int J Obes (Lond)2011; 35: S22–S25.
33. J.B.BuseS.CaprioW.T.Cefalu. How do we define cure of diabetes?Diabetes Care2009; 32: 2133–2135.
34. C.D.SjöströmL.LissnerL.Sjöström. Relationships between changes in body composition and changes in cardiovascular risk factors: the SOS Intervention Study. Swedish Obese Subjects. Obes Res1997; 5: 519–530.
35. L.KaskaJ.KobielaA.Abacjew-Chmylko. Nutrition and pregnancy after bariatric surgery. ISRN Obes2013; 2013: 492060–492060.
36. J.M.KellumS.M.ChikunguwoJ.W.Maher. Long-term results of malabsorptive distal Roux-en-Y gastric bypass in superobese patients. Surg Obes Relat Dis2011; 7: 189–193.
37. K.KanasakiM.KitadaM.Kanasaki. The biological consequence of obesity on the kidney. Nephrol Dial Transplant2013; 28(Suppl 4): iv1–7.
38. N.KambhamG.S.MarkowitzA.M.Valeri. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int2001; 59: 1498–1509.
39. D.HeberF.L.GreenwayL.M.Kaplan. Endocrine and nutritional management of the post-bariatric surgery patient: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab2010; 95: 4823–4843.
40. P.TondapuD.ProvostB.Adams-Huet. Comparison of the absorption of calcium carbonate and calcium citrate after Roux-en-Y gastric bypass. Obes Surg2009; 19: 1256–1261.
41. S.E.Williams. Metabolic bone disease in the bariatric surgery patient. J Obes2011; 2011: 634614–634614.
42. A.J.ColeL.M.BeckmanC.P.Earthman. Vitamin D status following bariatric surgery: implications and recommendations. Nutr Clin Pract2014; 29: 751–758.
43. S.V.LakhaniH.N.ShahK.Alexander. Small intestinal bacterial overgrowth and thiamine deficiency after Roux-en-Y gastric bypass surgery in obese patients. Nutr Res2008; 28: 293–298.
44. J.F.MerolaP.P.GhoroghchianM.A.Samuels. Clinical problem-solving. At a loss. N Engl J Med2012; 367: 67–72.
45. M.HatizifotisK.DolanL.Newbury. Symptomatic vitamin A deficiency following biliopancreatic diversion. Obes Surg2003; 13: 655–657.
46. M.J.EckertJ.T.PerryV.Y.Sohn. Incidence of low vitamin A levels and ocular symptoms after Roux-en-Y gastric bypass. Surg Obes Relat Dis2010; 6: 653–657.
47. T.ChaeR.Foroozan. Vitamin A deficiency in patients with a remote history of intestinal surgery. Br J Ophthalmol2006; 90: 955–956.
48. R.BolderyG.FieldingT.Rafter. Nutritional deficiency of selenium secondary to weight loss (bariatric) surgery associated with life-threatening cardiomyopathy. Heart Lung Circ2007; 16: 123–126.
49. A.M.Ramos-LevíA.Sánchez-PernauteM.A.Rubio Herrera. Dermatitis and optic neuropathy due to zinc deficiency after malabsortive bariatric surgery. Nutr Hosp2013; 28: 1345–1347.
50. S.F.CunhaG.A.GonçalvesJ.S.Marchini. Acrodermatitis due to zinc deficiency after combined vertical gastroplasty with jejunoileal bypass: case report. Sao Paulo Med J2012; 130: 330–335.
51. S.D.RobinsonB.CooperT.V.Leday. Copper deficiency (hypocupremia) and pancytopenia late after gastric bypass surgery. Proc (Bayl Univ Med Cent)2013; 26: 382–386.
52. I.F.BtaicheA.Y.YehI.J.Wu. Neurologic dysfunction and pancytopenia secondary to acquired copper deficiency following duodenal switch: case report and review of the literature. Nutr Clin Pract2011; 26: 583–592.
53. J.E.FriedmanR.M.DallalJ.L.Lord. Gouty attacks occur frequently in postoperative gastric bypass patients. Surg Obes Relat Dis2008; 4: 11–13.
54. B.M.QuesadaG.KohanH.E.Roff. Management of gallstones and gallbladder disease in patients undergoing gastric bypass. World J Gastroenterol2010; 16: 2075–2079.
55. J.C.LieskeR.KumarM.L.Collazo-Clavell. Nephrolithiasis after bariatric surgery for obesity. Semin Nephrol2008; 28: 163–173.
56. J.D.MachadoC.S.CamposC.Lopes Dah Silva. Intestinal bacterial overgrowth after Roux-en-Y gastric bypass. Obes Surg2008; 18: 139–143.
57. E.P.CeppaD.P.CeppaP.A.Omotosho. Algorithm to diagnose etiology of hypoglycemia after Roux-en-Y gastric bypass for morbid obesity: case series and review of the literature. Surg Obes Relat Dis2012; 8: 641–647.
58. R.A.SawayaJ.JaffeL.Friedenberg. Vitamin, mineral, and drug absorption following bariatric surgery. Curr Drug Metab2012; 13: 1345–1355.
59. M.A.Kominiarek. Preparing for and managing a pregnancy after bariatric surgery. Semin Perinatol2011; 35: 356–361.